215 related articles for article (PubMed ID: 8321910)
21. Development of a GC-MS method for quantitation of 2,3-dinor-TxB2 and determinations of the daily urinary excretion rates in healthy humans.
Vesterqvist O; Gréen K; Lincoln FH; Sebek OK
Thromb Res; 1984 Jan; 33(1):39-49. PubMed ID: 6695361
[TBL] [Abstract][Full Text] [Related]
22. Enhanced thromboxane biosynthesis in patients with chronic obstructive pulmonary disease. The Chronic Obstructive Bronchitis and Haemostasis Study Group.
Davì G; Basili S; Vieri M; Cipollone F; Santarone S; Alessandri C; Gazzaniga P; Cordova C; Violi F
Am J Respir Crit Care Med; 1997 Dec; 156(6):1794-9. PubMed ID: 9412557
[TBL] [Abstract][Full Text] [Related]
23. Increased thromboxane biosynthesis in type IIa hypercholesterolemia.
Davì G; Averna M; Catalano I; Barbagallo C; Ganci A; Notarbartolo A; Ciabattoni G; Patrono C
Circulation; 1992 May; 85(5):1792-8. PubMed ID: 1572035
[TBL] [Abstract][Full Text] [Related]
24. Renal metabolism and urinary excretion of thromboxane B2 in the rat.
Benigni A; Chiabrando C; Perico N; Fanelli R; Patrono C; FitzGerald GA; Remuzzi G
Am J Physiol; 1989 Jul; 257(1 Pt 2):F77-85. PubMed ID: 2750927
[TBL] [Abstract][Full Text] [Related]
25. Effects of unfractionated and low molecular weight heparins on platelet thromboxane biosynthesis "in vivo".
Landolfi R; De Candia E; Rocca B; Ciabattoni G; Antinori A; Masetti R; Patrono C
Thromb Haemost; 1994 Dec; 72(6):942-6. PubMed ID: 7740468
[TBL] [Abstract][Full Text] [Related]
26. Increased prostacyclin production during exercise in untrained and trained men: effect of low-dose aspirin.
Böger RH; Bode-Böger SM; Schröder EP; Tsikas D; Frölich JC
J Appl Physiol (1985); 1995 May; 78(5):1832-8. PubMed ID: 7649919
[TBL] [Abstract][Full Text] [Related]
27. Measurement of canine urinary thromboxanes by GC-MS and HPLC-RIA.
Tagari P; Callaghan DH; Black C; Yerge JA
Prostaglandins; 1994 Apr; 47(4):293-306. PubMed ID: 8041872
[TBL] [Abstract][Full Text] [Related]
28. Estimated rate of thromboxane secretion into the circulation of normal humans.
Patrono C; Ciabattoni G; Pugliese F; Pierucci A; Blair IA; FitzGerald GA
J Clin Invest; 1986 Feb; 77(2):590-4. PubMed ID: 3944270
[TBL] [Abstract][Full Text] [Related]
29. Pharmacokinetic and pharmacodynamic differences between two low dosages of aspirin may affect therapeutic outcomes.
Cerletti C; Dell'Elba G; Manarini S; Pecce R; Di Castelnuovo A; Scorpiglione N; Feliziani V; de Gaetano G
Clin Pharmacokinet; 2003; 42(12):1059-70. PubMed ID: 12959636
[TBL] [Abstract][Full Text] [Related]
30. Glucocorticoids impair platelet thromboxane biosynthesis in community-acquired pneumonia.
Cangemi R; Carnevale R; Nocella C; Calvieri C; Cammisotto V; Novo M; Castellani V; D'Amico A; Zerbinati C; Stefanini L; Violi F;
Pharmacol Res; 2018 May; 131():66-74. PubMed ID: 29577968
[TBL] [Abstract][Full Text] [Related]
31. Optimization of an enzyme immunoassay for 11-dehydro-thromboxane B(2) in urine: comparison with GC-MS.
Perneby C; Granström E; Beck O; Fitzgerald D; Harhen B; Hjemdahl P
Thromb Res; 1999 Dec; 96(6):427-36. PubMed ID: 10632465
[TBL] [Abstract][Full Text] [Related]
32. Effects of nabumetone on prostanoid biosynthesis in humans.
Cipollone F; Ganci A; Panara MR; Greco A; Cuccurullo F; Patrono C; Patrignani P
Clin Pharmacol Ther; 1995 Sep; 58(3):335-41. PubMed ID: 7554708
[TBL] [Abstract][Full Text] [Related]
33. Antibody-mediated extraction/negative-ion chemical ionization mass spectrometric measurement of thromboxane B2 and 2,3-dinor-thromboxane B2 in human and rat urine.
Chiabrando C; Benigni A; Piccinelli A; Carminati C; Cozzi E; Remuzzi G; Fanelli R
Anal Biochem; 1987 May; 163(1):255-62. PubMed ID: 3619026
[TBL] [Abstract][Full Text] [Related]
34. Urinary thromboxane A2 metabolites in patients presenting in the emergency room with acute chest pain.
Foegh ML; Zhao Y; Madren L; Rolnick M; Stair TO; Huang KS; Ramwell PW
J Intern Med; 1994 Feb; 235(2):153-61. PubMed ID: 8308478
[TBL] [Abstract][Full Text] [Related]
35. Thromboxane B2 urinary metabolites in patients undergoing cardiopulmonary bypass.
Jörres A; Chiabrando C; Kordonouri O; Schiessler A; Hess S; Farke S; Gahl GM; Müller C; Rivoltella L; Djurup R
Eicosanoids; 1992; 5(3-4):147-51. PubMed ID: 1292525
[TBL] [Abstract][Full Text] [Related]
36. Effects of very low dose and enteric-coated acetylsalicylic acid on prostacyclin and thromboxane formation and on bleeding time in healthy subjects.
Bode-Böger SM; Böger RH; Schubert M; Frölich JC
Eur J Clin Pharmacol; 1998; 54(9-10):707-14. PubMed ID: 9923572
[TBL] [Abstract][Full Text] [Related]
37. A critical evaluation of urinary immunoreactive thromboxane: feasibility of its determination as a potential vascular risk indicator.
Lorenz RL; Uedelhoven WM; Fischer S; Ruetzel A; Weber PC
Biochim Biophys Acta; 1989 Dec; 993(2-3):259-65. PubMed ID: 2597697
[TBL] [Abstract][Full Text] [Related]
38. Differential effect of aspirin on thromboxane and prostaglandin biosynthesis in man.
Ritter JM; Cockcroft JR; Doktor HS; Beacham J; Barrow SE
Br J Clin Pharmacol; 1989 Nov; 28(5):573-9. PubMed ID: 2590611
[TBL] [Abstract][Full Text] [Related]
39. Effects of two different HMG-CoA reductase inhibitors on thromboxane production in type IIA hypercholesterolemia.
Milani M; Cimminiello C; Lorena M; Arpaia G; Soncini M; Bonfardeci G
Biomed Pharmacother; 1996; 50(6-7):269-74. PubMed ID: 8952866
[TBL] [Abstract][Full Text] [Related]
40. Urinary 11-dehydro-thromboxane B2: a quantitative index of platelet activation in cerebral infarction.
Uyama O; Shimizu S; Nakanishi T; Nakahama H; Takiguchi A; Hayashi Y; Yamamoto S; Sugita M
Intern Med; 1992 Jun; 31(6):735-9. PubMed ID: 1392173
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
